This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Struthers, A. D. Articles by Ezan, E. Search for Related Content PubMed PubMed Citation Articles by Struthers, A. D. Articles by Ezan, E.

CLINICAL STUDIES

Nonadherence with angiotensin-converting enzyme inhibitor therapy

A comparison of different ways of measuring it in patients with chronic heart failure

Allan D. Struthers, MD^*, Robert MacFadyen, MD^*, Callum Fraser, PhD, Jess Robson^*, James J. Morton, PhD, Christophe Junot, BSc and Eric Ezan, PhD

^* Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK
Directorate of Biochemical Medicine, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK
CEA Service de Pharmacologie et d’Immunologie, Gif-sur-Yvette, France
Department of Medicine and Therapeutics, Western Infirmary, Glasgow, G11 6NT, UK

Manuscript received March 2, 1999; revised manuscript received June 18, 1999, accepted August 23, 1999.

Reprint requests and correspondence: Professor A. D. Struthers, Department of Clinical Pharmacology and Therapeutics, Ninewells Hospital, Dundee DD1 9SY, UK

OBJECTIVES

This study was designed to compare different proposed methods of assessing adherence with angiotensin-converting enzyme (ACE) inhibitor (ACEI) therapy in chronic heart failure.

BACKGROUND

The use of ACEIs in chronic heart failure gives us a unique opportunity to assess a patient’s adherence by measuring whether the expected biochemical effect of an ACEI is present in the patient’s bloodstream. In fact, there are several different ways of assessing ACE in vivo: these are serum ACE activity itself, plasma N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), urine AcSDKP, plasma angiotensin I (AI), plasma angiotensin II (AII), or the AII/AI ratio.

METHODS

Patients with chronic heart failure (n = 39) were randomized to regimens of ACEI nonadherence for one week, ACEI adherence for one week or two versions of partial adherence for one week, after which the above six tests were performed.

RESULTS

All six tests significantly distinguished between full nonadherence for one week and full or partial adherence. Only plasma AcSDKP produced a significantly different result between partial adherence and either full adherence or full nonadherence for one week. In terms of their ability to distinguish full nonadherence from full adherence, plasma AcSDKP was 89% sensitive and 100% specific with an area under its ROC of 0.95. Corresponding figures for urine AcSDKP were 92%, 97% and 0.95 and for serum ACE they were 86%, 95% and 0.90.

CONCLUSIONS

All six tests distinguished full nonadherence from all other forms of adherence. The rank order of performance was plasma AcSDKP, urine AcSDKP, serum ACE, AII/AI ratio and plasma AII followed by plasma AI.

Abbreviations and Acronyms   ACE = angiotensin-converting enzyme   ACEI = angiotensin-converting enzyme inhibitor   AI = Angiotensin I   AII = Angiotensin II   AcSDKP = N-acetyl-seryl-aspartyl-lysyl-proline   FAPGG = furylacrylolyphenylalanylglycylglycine

This article has been cited by other articles:

				M. Azizi, J. Menard, S. Peyrard, M. Lievre, M. Marre, and G. Chatellier Assessment of Patients' and Physicians' Compliance to an ACE Inhibitor Treatment Based on Urinary N-Acetyl Ser-Asp-Lys-Pro Determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) Study. Diabetes Care, June 1, 2006; 29(6): 1331 - 1336. [Abstract] [Full Text] [PDF]

				M. D Witham, S. D Hutcheon, C. G Fraser, M. E. McMurdo, and A. D Struthers Grossly elevated serum angiotensin-converting enzyme activities are still suppressible with ACE inhibitor therapy Journal of Renin-Angiotensin-Aldosterone System, June 1, 2002; 3(2): 138 - 138. [PDF]

				R J MacFadyen, C G Fraser, and A D Struthers Intermittent non-adherence with ACE inhibitor treatment and its implications for clinical trials results Heart, February 1, 2001; 85(2): 213 - 214. [Full Text]

				C. Berry Clinical implications of increased plasma angiotensin II concentrations despite ACE inhibitor therapy in patients with congestive heart failure: the issue of non-compliance with therapy Eur. Heart J., September 1, 2000; 21(17): 1484 - 1485. [PDF]

				C. Berry Clinical implications of increased plasma angiotensin II concentrations despite ACE inhibitor therapy in patients with congestive heart failure: the issue of non-compliance with therapy Eur. Heart J., September 1, 2000; 21(17): 1484 - 1485. [PDF]